Horizon Pharma
 |
|
| Public limited company | |
| Traded as | NASDAQ: HZNP |
| Industry | Healthcare |
| Founded | 2005 |
| Headquarters | Dublin, Ireland |
|
Key people
|
Timothy P. Walbert (Chairman, President & CEO) |
 $264 million (2014) |
|
| Website | www |
Timothy P. Walbert (Chairman, President & CEO)
Paul W. Hoelscher (CFO)
Robert F. Carey (CBO)
Horizon Pharma Public Limited Company (NASDAQ: HZNP) is a specialty pharmaceutical company that develops and markets medicine through its subsidiaries in the United States. The company was founded in 2005 and is based in Dublin, Ireland. The company focuses on developing treatments for arthritis, pain and inflammatory diseases. Horizon's product portfolio includes Actimmune (interferon gamma), Duexis (ibuprofen + famotidine), Pennsaid (diclofenac, 2% topical), and Rayos/Lodotra (prednisone). In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
The company's lead product base includes DUEXIS and RAYOS. Outside the United States, RAYOS is also known as LODOTRA.
The company has cooperated with American Gastroenterological Association (AGA) Institute to launch a program named “Connect to Protect” which aims to help physicians and patients better understand non-steroidal anti-inflammatory drug (NSAID) risks. The program is planned to promote communications between physicians and patients about NSAIDs and gastrointestinal ulcers.
In March 2014, the company completed the acquisition of Vidara Therapeutics International through a merge valued at about $660 million.
In October 2014, the company acquired the U.S. sales and marketing rights to the osteoarthritis drug Pennsaid from Nuvo Research for $45 million.
...
Wikipedia